Jacobs Levy Equity Management
OMED

Jacobs Levy Equity Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Jacobs Levy Equity Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-160,244
Closed -$120K – 1108
2018
Q4 		$120K Buy
160,244
+75,514
+89% +$114K ﹤0.01% 932
2018
Q3 		$180K Buy
84,730
+208
+0.2% +$498 ﹤0.01% 938
2018
Q2 		$195K Buy
84,522
+16,322
+24% +$47.5K ﹤0.01% 959
2018
Q1 		$217K Buy
68,200
+19,800
+41% +$54.6K ﹤0.01% 913
2017
Q4 		$198K Buy
48,400
+6,600
+16% +$28.7K ﹤0.01% 908
2017
Q3 		$189K Buy
+41,800
New +$169K ﹤0.01% 875
2017
Q2 		– Sell
-21,000
Closed -$193K – 1097
2017
Q1 		$193K Buy
+21,000
New +$184K ﹤0.01% 805
2016
Q3 		– Sell
-15,290
Closed -$188K – 1253
2016
Q2 		$188K Buy
+15,290
New +$186K ﹤0.01% 1017

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management's OMED Position: Q1 2019 in Review

Jacobs Levy Equity Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2019, closing a stake of 160,244 shares — an estimated $120K sold.

Jacobs Levy Equity Management first reported a position in OMED in Q2 2016 and held it in 8 quarters. The position peaked at $217K in Q1 2018. 41 funds tracked by Wall St. Rank hold OMED as of Q1 2019.

  • Jacobs Levy Equity Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 160,244 OncoMed Pharmaceuticals, Inc. shares in Q1 2019, an estimated $120K.
  • Jacobs Levy Equity Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2016 and held it in 8 quarters.
  • Jacobs Levy Equity Management's OncoMed Pharmaceuticals, Inc. position peaked at $217K in Q1 2018.
  • 41 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.